ClinicalTrials.gg
Not yet recruitingNCT07742527DynaMMic-2Updated Aug 3, 2026

A Study to Evaluate the Subcutaneous Belantamab (BCMAb) Formulation Versus Intravenous Belantamab in Participants With Multiple Myeloma While Treated With Standard of Care

A Phase 1 interventional study of Belantamab SC and Belantamab IV in Multiple Myeloma, sponsored by GlaxoSmithKline. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-03.

Sponsored by GlaxoSmithKline · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
22
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 42 studies in Multiple Myeloma by GlaxoSmithKline — 6 open to participants now, 20 under way, 7 of them phase 3. Multiple Myeloma · GlaxoSmithKline.

Planned enrollment
28th of 40
22 · median 41
Started
2026
with 3 others
Phase 1
12 of 42
2 open now
Primary completion
2027-08
later than 14 of 19 live
Registered
42nd of 42
by date

Among the 42 studies in Multiple Myeloma by GlaxoSmithKline, this one is the 28th largest by planned enrollment of the 40 interventional ones that give a count, is one of 4 that started in 2026, is one of 12 in phase 1, reaches primary completion later than 14 of the 19 other live ones, and was the 42nd registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

6 of the 42 studies in Multiple Myeloma by GlaxoSmithKline are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies in Multiple Myeloma by GlaxoSmithKline, or all of them as a file.
02

Study summary

This study aims to compare how belantamab behaves in the body when given as an injection under the skin (SC) versus into a vein (IV) in participants with multiple myeloma who are receiving standard of care treatment, to enable eventual development of SC formulation. It will assess how much belantamab is absorbed and how long it stays in the blood as well as assess whether it is safe and tolerated well by participants.

03

Conditions studied

  • Multiple Myeloma

Browse trials for

Keywords

  • Belantamab
  • Monoclonal antibody
  • B cell Maturation Antigen (BCMA)
  • Subcutaneous belantamab (BCMAb)
  • Intravenous
  • Subcutaneous
  • Multiple myeloma
  • Standard of care
  • First Line
  • Second Line
  • Maintenance
  • Autologous Stem Cell Transplant (ASCT) Maintenance treatment
  • DynaMMic
  • DynaMMic-2
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants are eligible to be included in the study only if all of the following criteria apply:

  • Participants at the time of signing the Form (ICF) must be aged 18 years old or greater or are of the legal age of consent in the jurisdiction in which the study is taking place.
  • or cytologically confirmed diagnosis of multiple myeloma (MM), as defined by the International Myeloma Working Group (IMWG).
  • Currently receiving maintenance therapy with either anti- cluster of differentiation 38 (anti-CD38) directed therapy, or lenalidomide, or both, following stem cell transplantation (ASCT) in either first or .
  • No change in current myeloma treatment for at least 2 months prior to during screening, or during the trial.
  • Partial response (PR) or better per IMWG per Investigator's assessment for at least 2 months prior to screening.
  • All current treatment-related toxicities (defined by National Cancer Institute (NCI CTCAE), version (v) 6.0, 2025) must be Grade less than or equal to (\<=) 2 at the time of screening except for alopecia (any grade), or endocrinopathy managed with replacement therapy (any grade).
  • ASCT must be greater than (>) 100 days prior to screening, and participants are transfusion independent and not receiving granulocyte colony-stimulating factor (G-CSF) or thrombopoietin analogies.
  • (ECOG) performance status of 0 to 2.
  • Have organ system functions as defined by the laboratory assessments.

Exclusion criteria

Exclusion Criteria:

Participants are excluded from the study if any of the following criteria apply:

  • Diagnosis of primary Amyloid Light chain (AL) Amyloidosis, active polyneuropathy, organomegaly, endocrinopathy, monoclonal plasma cell disorder, and skin changes (POEMS) syndrome, primary plasma cell leukemia, or non-secretory myeloma.
  • Any serious and/or unstable pre-existing medical, psychiatric disorder, or other conditions (including lab abnormalities) that could interfere with participant's safety, obtaining , or compliance with study procedures.
  • Has cirrhosis or current unstable liver or biliary disease per investigator assessment defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal/gastric varices, or persistent jaundice.
  • Known immediate or delayed reaction or idiosyncrasy to drugs chemically related to belantamab, or hyaluronidase, or any of the components of the study treatment. History of severe hypersensitivity to other monoclonal antibodies (mAbs).
  • Active infection requiring antibiotic, antiviral, or antifungal treatment.
  • Presence of active renal condition (infection, requirement for dialysis or any other condition that could affect participant's safety).
  • Prior B cell maturation antigen (BCMA) directed therapy.
  • Plasmapheresis within 7 days prior to the first dose of study drug.
  • Any major surgery (other than bone-stabilizing surgery) within 2 weeks of first dose or has not recovered fully from surgery.
  • Participants must not receive live/ within 30 days prior to first dose of study treatment or whilst receiving belantamab for at least 70 days following last study treatment.
  • Is currently enrolled or has participated in any other clinical study involving an study intervention or any other type within 60 days of an investigational medicinal product before randomization.
  • Known (HIV) infection, unless the participant can meet all the following criteria:

    • Established antiretroviral therapy (ART) for at least 4 weeks and HIV viral load \<400 copies/milliliter (mL)
    • CD4+ T-cell (CD4+) counts greater than or equal to (>=) 350 cells/microliter (uL)
    • No history of acquired immunodeficiency syndrome (AIDS)-defining opportunistic infections within the last 12 months
  • Participants with virus (HBV) infection will be excluded
  • Positive antibody test result or positive hepatitis C ribonucleic acid (RNA) test result at screening or within 3 months prior to first dose of study treatment unless the participant can meet the following criteria:

    • RNA test negative
    • Successful antiviral treatment (usually 8 weeks duration) is required, followed by a negative hepatitis C virus (HCV) RNA test after a of at least 4 weeks.
  • Is pregnant or breastfeeding.
  • Evidence of cardiovascular risk including any of the following:

    • Evidence of current untreated arrhythmias, including, but not limited to, clinically significant (ECG) abnormalities such as 2nd degree (Mobitz Type II) or 3rd degree atrioventricular (AV) block.
    • History of myocardial infarction (MI), acute coronary syndromes (including unstable angina), coronary angioplasty, stenting or bypass grafting, all within three months of screening.
    • Class III or IV heart failure as defined by the (NYHA) functional classification system.
    • Uncontrolled hypertension.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
22 participants (estimated)

Study arms

  • Experimental
    Belantamab SC Dose level (DL)1 /IV DL1/SC DL 2 /SC DL1

    Participants will receive Belantamab subcutaneous (SC) dose level 1 (DL1) +Recombinant Human Hyaluronidase PH20 (rHuPH20) in Period 1; followed by Belantamab intravenous (IV) DL1 in Period 2; followed by Belantamab SC DL2 + rHuPH20 in Period 3; further followed by Belantamab SC DL1 + rHuPH20 in Period 4. Dose level 1 is the lowest dose level.

    Drug: Belantamab SC · Drug: Belantamab IV · Drug: Recombinant Human Hyaluronidase PH20 (rHuPH20) · Drug: Standard of care

  • Experimental
    Belantamab IV DL1 /SC DL1 /SC DL2 /SC DL1

    Participants will receive Belantamab IV DL1 in Period 1; followed by Belantamab SC DL1 + rHuPH20 in Period 2; followed by Belantamab SC DL2 + rHuPH20 in Period 3; further followed by Belantamab SC DL1 + rHuPH20 in Period 4 of the study. Dose level 1 is the lowest dose level.

    Drug: Belantamab SC · Drug: Belantamab IV · Drug: Recombinant Human Hyaluronidase PH20 (rHuPH20) · Drug: Standard of care

Interventions

  • Belantamab will be administered via SC route.

    Also known as: GSK2857914

  • Belantamab will be administered via IV route.

    Also known as: GSK2857914

  • rHuPH20 will be administered via SC route.

  • DrugStandard of care

    Participants will receive standard of care: Lenalidomide and/or anti-CD38 mAb as maintenance therapy.

06

What researchers measure

Primary outcomes

  1. Bioavailability of belantamab

    Time frame: Up to approximately 42 weeks

  2. Maximum observed plasma concentration (Cmax) of belantamab

    Time frame: Up to approximately 42 weeks

  3. Area under concentration-time curve (AUC) of belantamab

    Time frame: Up to approximately 42 weeks

  4. Plasma concentration of belantamab

    Time frame: Up to approximately 42 weeks

  5. Number of Participants with Adverse Events (AE)

    Time frame: Up to approximately 42 weeks

  6. Number of participants with changes in laboratory parameters

    Time frame: Up to approximately 42 weeks

  7. Number of participants with changes in vital signs

    Time frame: Up to approximately 42 weeks

Secondary outcomes

  1. Number of participants with Anti-drug antibodies (ADA) against belantamab

    Time frame: Up to approximately 71 weeks

  2. Titers of ADA against belantamab

    Time frame: Up to approximately 71 weeks

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No — Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/gsk-patient-level-data-sharing-july2025.pdf

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Aug 2027, 9 months later.

Of 212 industry-sponsored phase 1 interventional studies under Multiple Myeloma, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 71. This study's planned 9 months is below that.

Counting every sponsor, half of 413 studies reached it within 50 months; a quarter within 33 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 29, 2026
First posted
Aug 3, 2026
StartEst.
Oct 16, 2026
Primary completionEst.
Aug 5, 2027
CompletionEst.
Mar 18, 2030
Last update
Aug 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07742527
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Aug 3, 2026
Start date
Oct 16, 2026 (estimated)
Primary completion
Aug 5, 2027 (estimated)
Completion
Mar 18, 2030 (estimated)
Last update
Aug 3, 2026

Study contacts

US GSK Clinical Trials Call Center
Contact
GSKClinicalSupportHD@gsk.com
877-379-3718
EU GSK Clinical Trials Call Center
Contact
GSKClinicalSupportHD@gsk.com
+44 (0) 20 89904466

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Belantamab · Hyaluronidase (human recombinant)

Start the discussion